Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.52 |
| ▸ | BMP1 | P13497 | 4/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 6/20 | 0.45 |
| ▸ | MMP2 | P08253 | 5/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzenesulfonamide SCHEMBL6323755 | 0.83 | TAS2R14 (0.53) | TAS2R14BMP1KEAP1NFE2L2PTGES | |
| SCHEMBL6325795 | 0.78 | TAS2R14 (0.61) | TAS2R14BMP1KEAP1NFE2L2PTGES | |
| SCHEMBL6324157 | 0.78 | TAS2R14 (0.61) | TAS2R14BMP1KEAP1NFE2L2PTGES | |
| SCHEMBL6324153 | 0.78 | TAS2R14 (0.61) | TAS2R14BMP1KEAP1NFE2L2PTGES | |
| SCHEMBL6323929 | 0.76 | TAS2R14 (0.58) | TAS2R14BMP1KEAP1NFE2L2PTGES | |
| SCHEMBL6330875 | 0.76 | TAS2R14 (0.58) | TAS2R14BMP1KEAP1NFE2L2PTGES | |
| SCHEMBL7343979 | 0.76 | KEAP1 (0.81) | TAS2R14BMP1KEAP1NFE2L2PTGES | |
| SCHEMBL6323924 | 0.76 | TAS2R14 (0.58) | TAS2R14BMP1KEAP1NFE2L2PTGES | |
| SCHEMBL7348080 | 0.76 | KEAP1 (0.81) | TAS2R14BMP1KEAP1NFE2L2PTGES | |
| SCHEMBL6322381 | 0.75 | TAS2R14 (0.64) | TAS2R14BMP1KEAP1NFE2L2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | TAS2R14 1996/4885BMP1 2254/4885KEAP1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.